Bayer de Mexico, S.A. de C.V.
⚠️ High Risk
FEI: 3002806479 • Lerma, Mexico • MEXICO
FEI Number
3002806479
Location
Lerma, Mexico
Country
MEXICOAddress
Carretera Mexico-Toluca Km. 52.5, , Lerma, Mexico, Mexico
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
INCONSPICU
Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.
DR QUALITY
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the article appears to be represented as a drug the name of which is recognized in an official compendium and its strength appears to differ from or its quality or purity appear to fall below the standards set forth in such compendium.
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
UNSAFE COL
The article appears to be, or to bear or contain a color additive which is unsafe within the meaning of Section 721(a).
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
NUTRIT LBL
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.
NEW VET DR
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.
FALSE
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose labeling appears to be false or misleading.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 9/18/2025 | 61EDA08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/16/2024 | 62GCA49NAPROXEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/4/2024 | 61XCA08CHLORPHENIRAMINE MALEATE (ANTI-HISTAMINIC) | Division of Southeast Imports (DSEI) | |
| 10/8/2024 | 65JDY39DROSPIRENONE | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/27/2024 | 54AGA13VITAMIN C (ASCORBIC ACID) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/29/2024 | 61EDA08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/4/2024 | 60CDY09PHENYLEPHRINE HCL (ADRENERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/13/2024 | 60CCL48OXYMETAZOLINE HCL (ADRENERGIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/13/2024 | 62GCY46KETOPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/8/2024 | 61WCJ04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/16/2024 | 62GCA46KETOPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/28/2023 | 60LCA05ASPIRIN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/10/2023 | 65CCA99NUTRIENT/TONIC N.E.C. | Division of Southeast Imports (DSEI) | |
| 10/6/2022 | 62GAA50NAPROXEN SODIUM (ANTI-INFLAMMATORY) | Division of Southeast Imports (DSEI) | |
| 10/6/2022 | 62GAA50NAPROXEN SODIUM (ANTI-INFLAMMATORY) | Division of Southeast Imports (DSEI) | |
| 10/6/2022 | 54CRN23L-CARNITINE (PROTEIN) | 72NEW VET DR | Division of Southeast Imports (DSEI) |
| 7/8/2022 | 61XCA08CHLORPHENIRAMINE MALEATE (ANTI-HISTAMINIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/1/2022 | 61WCJ04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/8/2022 | 61PCY99ANTI-DIABETIC N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/16/2021 | 62GDA49NAPROXEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/22/2021 | 64GCY07ESTRADIOL (ESTROGEN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/22/2021 | 62GCY41IBUPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/22/2021 | 62GCY50NAPROXEN SODIUM (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/27/2021 | 60SBA99ANTACID, N.E.C. | 118NOT LISTED | Division of Southwest Imports (DSWI) |
| 6/22/2021 | 61XCA08CHLORPHENIRAMINE MALEATE (ANTI-HISTAMINIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/19/2021 | 54ADY02VITAMIN B1 (THIAMINE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/5/2021 | 62GCA49NAPROXEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/22/2021 | 65PCB04VARDENAFIL | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 3/1/2021 | 60LCA05ASPIRIN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/1/2021 | 61LCA42RIVAROXABAN | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/27/2020 | 60LAA05ASPIRIN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/2/2020 | 56GDJ99ANTIFUNGAL N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/29/2020 | 61LDY42RIVAROXABAN | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/17/2020 | 62VCY99ANTI-VIRAL N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/28/2019 | 54ACA90MULTIPLE VITAMINS (MVI-12 VITAMIN COMBO) (VITAMIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/28/2019 | 54ACA05VITAMIN B12 (CYANOCOBALAMIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/4/2019 | 60LDA05ASPIRIN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/4/2019 | 56ODA02MOXIFLOXACIN HCL (FLUOROQUINOLONE) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/3/2018 | 60SBS99ANTACID, N.E.C. | Division of Southwest Imports (DSWI) | |
| 1/12/2018 | 61WDY04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/7/2017 | 60SBS99ANTACID, N.E.C. | Division of Southwest Imports (DSWI) | |
| 11/2/2017 | 62GCE41IBUPROFEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/2/2017 | 60LCY05ASPIRIN (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/11/2017 | 60SDA99ANTACID, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/15/2017 | 66FDB02SULFAPYRIDINE (SUPPRESSANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/10/2017 | 61WBJ04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 2/7/2017 | 64GDA19ETHINYL ESTRADIOL (ESTROGEN) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/30/2016 | 54ACY99VITAMIN, N.E.C. | New Orleans District Office (NOL-DO) | |
| 4/1/2016 | 66VCA99MISCELLANEOUS PATENT MEDICINES, ETC. | Florida District Office (FLA-DO) | |
| 2/29/2016 | 60LCA08BENZYDAMINE HCL (ANALGESIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2016 | 62GCY94KETOROLAC TROMETHAMINE (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2016 | 61ECY08LORATADINE (ANTI-ASTHMATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2016 | 62VCY01AMANTADINE HCL (ANTI-VIRAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2016 | 62KCY10OMEPRAZOLE (ANTI-PERISTALTIC, ANTI-DIARRHEAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2016 | 62GCY54OXAPROZIN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/28/2015 | 60SBS99ANTACID, N.E.C. | Southwest Import District Office (SWI-DO) | |
| 8/27/2014 | 60SBA99ANTACID, N.E.C. | Southwest Import District Office (SWI-DO) | |
| 9/23/2013 | 61WBO04CLOTRIMAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC) | Southwest Import District Office (SWI-DO) | |
| 6/20/2013 | 66VCC99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 6/13/2013 | 60SBA99ANTACID, N.E.C. | Southwest Import District Office (SWI-DO) | |
| 6/13/2013 | 60SBA99ANTACID, N.E.C. | 115DR QUALITY | Southwest Import District Office (SWI-DO) |
| 6/13/2013 | 60SBA99ANTACID, N.E.C. | 115DR QUALITY | Southwest Import District Office (SWI-DO) |
| 12/7/2011 | 64GCB29LEVONORGESTREL (ESTROGEN) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 11/14/2011 | 64GCB29LEVONORGESTREL (ESTROGEN) | 75UNAPPROVED | New Orleans District Office (NOL-DO) |
| 11/29/2010 | 65RBY18SODIUM BICARBONATE (REPLENISHER) | Southwest Import District Office (SWI-DO) | |
| 8/30/2010 | 60SBC99ANTACID, N.E.C. | 118NOT LISTED | Southwest Import District Office (SWI-DO) |
| 9/16/2009 | 60LBO01ACETAMINOPHEN (ANALGESIC) | Southwest Import District Office (SWI-DO) | |
| 9/16/2009 | 60LBY01ACETAMINOPHEN (ANALGESIC) | Southwest Import District Office (SWI-DO) | |
| 9/16/2009 | 60LBY01ACETAMINOPHEN (ANALGESIC) | Southwest Import District Office (SWI-DO) | |
| 11/5/2008 | 62GAY49NAPROXEN (ANTI-INFLAMMATORY) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/5/2008 | 60LBA99ANALGESIC, N.E.C. | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 11/5/2008 | 60LBY01ACETAMINOPHEN (ANALGESIC) | 75UNAPPROVED | Southwest Import District Office (SWI-DO) |
| 3/24/2003 | 41BHT99FOODS WITH SUPPLEMENTAL NUTRIENTS ADDED, WITH OR WITHOUT ARTIFICAL SWEETNERS | 11UNSAFE COL | Southwest Import District Office (SWI-DO) |
Frequently Asked Questions
What is Bayer de Mexico, S.A. de C.V.'s FDA import refusal history?
Bayer de Mexico, S.A. de C.V. (FEI: 3002806479) has 73 FDA import refusal record(s) in our database, spanning from 3/24/2003 to 9/18/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Bayer de Mexico, S.A. de C.V.'s FEI number is 3002806479.
What types of violations has Bayer de Mexico, S.A. de C.V. received?
Bayer de Mexico, S.A. de C.V. has been cited for 11 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Bayer de Mexico, S.A. de C.V. come from?
All FDA import refusal data for Bayer de Mexico, S.A. de C.V. is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.